Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update Meeting Abstract
| Authors: | Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; Rizvi, N.; Crino, L.; Reck, M.; Eberhardt, W. E.; Hellmann, M.; Geese, W. J.; Li, A.; Healey, D.; Brahmer, J. R.; Paz-Ares, L. |
| Abstract Title: | Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi420 |
| Language: | English |
| ACCESSION: | WOS:000393913000307 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdw383.15 |
| Notes: | Meeting Abstract: 1215PD -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work